Persistence of HBV-DNA in children with chronic hepatitis B who seroconverted to anti-HBs antibodies after interferon-alpha therapy: correlation with specific IgG subclass responses to HBsAg.

[1]  M. Sakamoto,et al.  Persistence of hepatitis B viremia after recovery from acute hepatitis B: correlation between anti-HBc titer and HBV DNA in serum. , 2002, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  M. Grace,et al.  Interferon‐α as an immunotherapeutic protein , 2002, Journal of Leukocyte Biology.

[3]  K. Kidd‐Ljunggren,et al.  Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. , 2000, Journal of hepatology.

[4]  J. Bartolomé,et al.  Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen–negative cases , 2000, Hepatology.

[5]  K. Madaliński,et al.  IgG subclass distribution of hepatitis B surface antigen antibodies induced in children with chronic hepatitis B infection after interferon-alpha therapy. , 2000, Journal of Infectious Diseases.

[6]  K. Madaliński,et al.  The IgG subclass profile of anti-HBs response in vaccinated children and children seroconverted after natural infection. , 2000, Vaccine.

[7]  G. Gerken,et al.  The presence of high amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBV-induced immune response. , 1999, Journal of hepatology.

[8]  Mei‐Hwei Chang.  Chronic hepatitis virus infection in children , 1998, Journal of gastroenterology and hepatology.

[9]  K. Koike,et al.  Persistent viremia after recovery from self‐limited acute hepatitis B , 1998, Hepatology.

[10]  N. Hayashi,et al.  A molecular analysis of viral persistence in surface antigen‐negative chronic hepatitis B , 1996, Hepatology.

[11]  E. Brunt,et al.  Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen. , 1991, Annals of internal medicine.

[12]  H. Thomas,et al.  Incidence of hepatitis B viraemia, detected using the polymerase chain reaction, after successful therapy of hepatitis B virus carriers with interferon–α , 1991, Journal of medical virology.

[13]  I. Mushahwar,et al.  Viral hepatitis, type B. Studies on natural history and prevention re-examined. , 1979, The New England journal of medicine.

[14]  R. Steinman,et al.  EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. , 2001, The Journal of clinical investigation.

[15]  R. Zinkernagel,et al.  Antiviral immunity. , 1997, Immunology today.

[16]  F. Chisari,et al.  Hepatitis B virus immunopathogenesis. , 1995, Annual review of immunology.

[17]  W. Britt,et al.  Epitope-specific distribution of IgG subclasses against antigenic domains on glycoproteins of human cytomegalovirus. , 1994, The Journal of infectious diseases.

[18]  F. Chisari,et al.  Hepatitis B virus persistence after recovery from acute viral hepatitis. , 1994, The Journal of clinical investigation.

[19]  K. Madaliński,et al.  Isolation and partial characterization of circulating immune complexes in sera of children with HBV-mediated glomerulonephritis. , 1991, Archivum immunologiae et therapiae experimentalis.